Therapy for ulcerative colitis

Current Opinion in Gastroenterology

Volumn 14, Issue 4, 1998, Pages 312-316

  Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; FOLIC ACID; FOLINIC ACID; HEPARIN; LIPOXYGENASE INHIBITOR; MESALAZINE; NICOTINE; SUCROSE POLYESTER; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CELL PROLIFERATION; DELAYED RELEASE FORMULATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ESCHERICHIA COLI; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; RECTAL DRUG ADMINISTRATION; RECTUM CARCINOMA; REVIEW; TOXICITY; TRANSDERMAL DRUG ADMINISTRATION; ULCERATIVE COLITIS;

EID: 0031856492     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199807000-00007     Document Type: Review

References (60)

1. Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults. • Am J Gastroenterol 1997, 92:204-211. Practice guidelines for the clinical care of adults with UC.
2. Ardizzone S, Molteni P, Bollani S, Bianchi Porro G: Guidelines for the treatment of ulcerative colitis in remission. Eur J Gastroenterol 1997, 9:836-843.
3. Tremaine WJ: Issues in the development of practice guidelines for inflammatory bowel disease. Inflamm Bowel Dis 1997, 3:284-287.
4. Sutherland LR, Hanauer SB, Scholmerich J, and the Task Force on Clinical Trials of the International Organisation for the Study of Inflammatory Bowel Disease: Standards for clinical trials of therapy in inflammatory bowel disease. Inflamm Bowel Dis 1997, 3:277-283.
5. Fredd S: Standards for approval of new drugs for IBD. Inflamm Bowel Dis 1995, 1:284-294.
6. Ilnyckyj A, Shanahan F, Anton PA, Cheang M, Bernstein CN: Quantification of the placebo response in ulcerative colitis. Gastroenterology 1997, 112:1854-1858.
7. Sutherland LR, May GR, Shaffer EA: Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993, 118:540-549.
8. Sutherland LR, Roth DE, Beck PL: Alternatives to sulfasalazine: a metaanalysis of 5-ASA in the treatment of ulcerative colitis, Inflamm Bowel Dis 1997, 3:65-78.
9. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, Koval G, •• Nichols T, Targan S, Fleishman C, et al.: A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997, 92:1867-1871. Randomized, controlled trial demonstrating the additive benefit of combination oral and rectal 5-ASA therapy in patients with active UC.
10. d'Albasio G, Pacini F, Camarri E, Messori A, Trallori G, Bonanomi AG, •• Bardazzi G, Milla M, Biagini M, Quaranta S, et al.: Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 1997, 92: 1143-1147. Randomized, controlled trial demonstrating the additive benefit of combination oral and rectal 5-ASA therapy in patients with active UC.
11. Schreiber S, Hamling J, Zehnter E, Howaldt S, Daerr W, Raedler A, Kruis W: Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 1997, 40:761-766.
12. Hanauer SB, Verst-Brasch C, Regalli G: Renal safety of long-term mesalamine therapy in inflammatory bowel disease (IBD). Gastroenterology 1997, 112:A991.
13. Marshall JK, Irvine EJ: Rectal corticosteriods versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997, 40:775-781.
14. Keller R, Stoll R, Foerster EC, Gutsche N, Domschke W: Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial. Aliment Pharmacol Ther 1997, 11:1047-1052.
15. Lofberg R, Danielsson A, Suhr O, Nilsson A, Schioler R, Nyberg A, Hultcrantz R, Kollberg B, Gillberg R, Willen R, et al.: Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996, 110:1713-1718.
16. Lindgren S, Suhr O, Persson T, Pantzar N: Treatment of active distal ulcerative colitis (UC) and maintenance or remission with Entocort enema: a randomised controlled dosage study. Gut 1997, 41 (suppl 3):A223.
17. Kornbluth A, Present DH, Lichtiger S, Hanauer S: Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol 1997, 92:1424-1428.
18. Atkinson KA, McDonald JWD, Lamba B, Feagan BG: Intravenous cyclosporine for severe attacks of ulcerative colitis: a survey of Canadian gastroenterologists. Can J Gastroenterol 1997, 11:583-587.
19. Hyde GM, Thillainayagam AV, Jewell DP: Intravenous cyclosporin as • rescue therapy in severe ulcerative colitis: time for a reappraisal? Gastroenterology 1997. 112:A1002. Important review from Oxford University of the use and benefit of cyclosporine in 178 patients with severe UC.
20. Mahadevan U, Kornbluth AA, Goldstein E, George J, Lichtiger S, Present DH: Is cyclosporine (CS) induced nephrotoxicity permanent or progressive in patients with inflammatory bowel disease (IBD)? Gastroenterology 1997, 112:A1030.
21. Feutren G, Mihatsch MJ, for the International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases: Risk factors for cyclosporineinduced nephropathy in patients with autoimmune diseases. N Engl J Med 1992, 326:1654-1660.
22. Stein R, Cohen R, Hanauer S: Complications during cyclosporine therapy for inflammatory bowel disease. Gastroenterology 1997, 112:A1096. Important review of the serious complications resulting from the use of cyclosporine in patients with severe UC.
23. Scott AM, Myers GA, Harms BA: Pneumocystis carinii pneumonia postrestorative proctocolectomy for ulcerative colitis: a role for perioperative prophylaxis in the cyclosporine era? Report of a case and review of the literature. Dis Colon Rectum 1997, 40:973-976.
24. Quan VA, Saunders BP, Hicks BH, Sladen GE: Cyclosporin treatment for ulcerative colitis complicated by fatal Pneumocystis carinii pneumonia. BMJ 1997, 314:363-364.
25. Sandborn WJ: Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizmg Crohn's disease. Am J Gastroenterol 1997, 92:876-879.
26. Bousvaros A, Wang A, Leichtner AM: Tacrolimus (FK506) treatment of fulminant colitis in a child. J Pediatr Gastroenterol Nutr 1996, 23:329-333.
27. Bousvaros A, Kirschner B, Werlin S, Balint J, Kendall R, Griffiths A, Leichtner, for the Pediatric Gastroenterology Collaborative Research Group: Oral tacrolimus treatment of severe colitis in children. Gastroenterology 1997, 112:A941.
28. Fellerman K, Ludwig D, Stahl M, David-Walek T, Hriesek C, Stange EF: Tacrolimus in steroid-refractory inflammatory bowel disease (IBD). Gastroenterology 1997, 112:A971.
29. Sandborn WJ, Tremaine WJ, Offord KP, Lawson GM, Petersen BT, Batts •• KP, Croghan IT, Dale LC, Schroeder DR, Hurt RD: Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997, 126:364-371. Randomized, controlled trial demonstrating the efficacy of transdermal nicotine in patients with active UC.
30. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, Newcombe RG, Russell MAH, Feyerabend C, Thomas GAO, et al.: Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994, 330:811-815.
31. Green JT, Thomas GAO, Rhodes J, Evans BK, Russell MAH, Feyerabend C, Fuller GS, Newcombe RG, Sandborn WJ: Pharmacokinetics of nicotine carbomer enemas: a new treatment modality for ulcerative colitis. Clin Pharmacol Ther 1997, 61:340-348.
32. Zins BJ, Sandborn WJ, Mays DC, Lawson GM, McKinney JA, Tremaine WJ, Mahoney DW, Zinsmeister AR, Hurt RD, Offord KP, et al.: Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous nicotine tartrate administration. J Clin Pharmacol 1997, 37:426-436.
33. Compton RF, Sandborn WJ, Lawson GM, Sheets AJ, Mays DC, Zins BJ, Tremaine WJ, Lipsky JJ, Mahoney DW, Zinsmeister AR, et al.: A doseranging pharmacokinetic study of nicotine tartrate following single dose delayed-release oral and intravenous administration, Aliment Pharmacol Ther 1997, 11:865-874.
34. Sandborn WJ, Tremaine WJ, Leighton JA, Lawson GM, Zins BJ, Compton RF, Mays DC, Lipsky JJ, Batts KP, Offord KP, et al.: Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment Pharmacol Ther 1997, 11:663-671.
35. Green JT, Thomas GAO, Rhodes J, Williams GT, Evans BK, Russell MAH, Feyerabend C, Rhodes P, Sandborn WJ: Nicotine enemas for active ulcerative colitis: a pilot study. Aliment Pharmacol Ther 1997, 11:859-863.
36. Sands BE: Biologic therapy for inflammatory bowel disease. Inflamm Bowel Dis 1997, 3:95-113.
37. Targan SR, Hanauer SB, Van Deventer SJH, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ, for the Crohn's Disease cA2 Study Group: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997, 337:1029-1035.
38. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long A, Forbes A, Kamm MA: Randomised controlled trial of CDP571 antibody to tumor necrosis factor-alpha in Crohn's disease. Lancet 1997, 349:521-524.
39. Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes JM: • Treatment of ulcerative colitis with an engineered human anti-TNFα antibody CDP571. Aliment Pharmacol Ther 1997, 11:1031-1035. Pilot study suggesting that anti-TNFα antibody may be beneficial in active UC.
40. Sands EE, Podolsky DK, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauei SB, Mayer L, Targan SR, DeWoody KL, Braakman TAJ, et al.: Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe. steroid-refractory ulcerative colitis (UC). Gastroenterology 1996, 110:A1008.
41. Watkins PE, Warren BF, Stephens S, Ward P, Foulkes R: Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumor necrosis factor alpha. Gut 1997, 40:628-633.
42. Korzenik JR; IBD: a vascular disorder? The case for heparin therapy. Inflamm Bowel Dis 1997, 3:87-94.
43. Evans RC, Shim Wong RC, Rhodes JM: Treatment of corticosteroid-resistant ulcerative colitis with heparin: a report of 16 cases. Aliment Pharmacol Ther 1997, 11:1037-1040.
44. Folwaczny C, Fricke H, Endres S, Jochum M, Loeschke K: Anti-inflammatory properties of unfractionated heparin in patients with highly active ulcerative colitis. Am J Gastroenterol 1997, 92:911-912.
45. Gaffney PR, O'Leary JJ, Doyle CT, Gaffney A, Hogan A, Smew F, Annis P; Response to heparin in patients with ulcerative colitis. Lancet 1991, 337:238-239.
46. Gaffney PR, Doyle CT, Gaffney A, Hogan A, Hayes DP, Annis P: Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroeiterol 1995, 90:220-223.
47. Roberts WG. Simon TJ, Berlin RG, Haggitt RC, Snyder ES, Stenson WF, •• Hanauer SB, Reagan JE, Cagliola A, Tanaka WK, et al.: Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology 1997, 112:725-732. Randomized, controlled trial demonstrating that the 5-lipoxygenase inhibitor MK-591 is not effective against active UC.
48. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF, and the •• European Zileuton Study Group for Ulcerative Colitis: A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis Gastroenterology 1997, 112:718-724. Randomized, controlled trial demonstrating that the 5-lipoxygenase inhibitor Zileuton is not effective for remission maintenance in patients with UC.
49. Breuer RI, Soergel KH, Lashner BA, Christ ML, Hanauer SB, Vanagunas •• A, Hang JM, Keshavarzian A, Robinson M, Sellin JH, et al.: Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial, Gut 1997, 40:485-491. Randomized, controlled trial demonstrating that short-chain fatty-acid enemas are not effective against active UC.
50. Steinhart AH, Hiruki T, Brzezinski A, Baker JP: Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 1996, 10:729-736.
51. Scheppach W, German-Austrian SCFA Study Group. Treatment of distal ulcerative colitis with short-chain fatty acid enemas: a placebo-controlled trial. Dig Dis Sci 1996, 41:2254-2259.
52. Vernia P, Marcheggiano A, Caprilli R, Frieri G, Corrao G, Valpiani D, Di Paolo MC, Paoluzi P, Torsili A: Short chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther 1995, 9:309-313.
53. Zorich NL, Jones MB, Kesler JM, Carter SB, Sutton MA, Bayless T, for the Olestra in IBD Study Group: A randomized, double-blind study of the effect of olestra on disease activity in patients with quiescent IBD. Am J Med 1997, 103:389-399.
54. Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, •• Florakis N, Petraki K, Spiliadi CH, Triantafyllou G: A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997, 92:454-456. Randomized, controlled trial demonstrating that ciprofloxacin is not effective in active UC.
55. Turunen U, Farkkila M, Hakala K, Vuoristo M, Rahm V, Seppala K, Valtonen V, Miettinen TA: A double-blind, placebo controlled six-month ciprofloxacin treatment improves prognosis in ulcerative colitis. Gastroenterology 1994, 106:A786.
56. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M: Double-blind •• comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997, 11:853-858. Randomized, controlled trial demonstrating that probiotic bacterial therapy is effective for remission maintenance in patients with UC.
57. Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A: The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997, 112:29-32.
58. Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB: Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. Gastroenterology 1989, 97:255-259.
59. Lashner BA: Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. J Cancer Res Clin Oncol 1993, 119:549-554.
60. Biasco G, Zannoni U, Maria Paganelli G, Santuccr R, Gionchetti P, Rivolta •• G, Miniero R, Pironi L, Calabrese C, Di Febo G, et al.: Folic acid supplementation and cell kinetics of rectal mucosa in patients with ulcerative colitis. Cancer Epidemiol Biomarkers & Prev 1997, 6:469-471. Small, randomized, controlled trial suggesting that folinic acid may be effective (using an intermediate biomarker endpoint) as a chemoprevention agent in patients with longstanding UC.